Lucid Diagnostics (LUCD) Q3 2026 earnings review
Medicare starts paying Lucid Diagnostics, and October test volume jumps
Lucid Diagnostics, the maker of the EsoGuard DNA test for esophageal precancer, won its first Medicare payments in October even though third-quarter sales barely moved. Revenue held at $1.2 million on 2,871 tests as the laboratory waited on insurers. Then its regional Medicare contractor began paying claims case by case at $1,938 per test, and chief executive Lishan Aklog reported a record month of more than 1,800 tests in October.
| Revenue | $1.20M -0.7% from a year ago |
|---|---|
| EsoGuard tests performed | 2,871 +1.1% from a year ago |
| October monthly test volume | >1,800 record month after Medicare starts paying |
| Concert health plan outlook | Raised to 5 up from 3 plans adopted last quarter |
⚖️ Verdict: 🟢 Bullish
The story got better because Medicare is now paying for the test, removing the main barrier that kept quarterly sales near $1 million. Winning case-by-case reimbursement and seeing October volume nearly double the third-quarter monthly pace shows doctors will order the test once older patients are covered. One caution: the formal national Medicare coverage rule is still stuck in a federal backlog, and cash dropped by $15 million in the quarter, forcing another $15 million preferred-stock raise.
The question now is whether case-by-case Medicare billing can turn October's testing surge into steady cash revenue before the formal coverage policy arrives. If the regional contractor keeps paying promptly at $1,938 per test, revenue will climb and cash burn will shrink; if manual reviews bog down as claim volume rises, the expanded sales team will quickly drain the new $15 million financing. Fourth-quarter revenue and cash collection will tell.
🐂 Bull Case
Medicare Starts Paying Before the Formal Policy Arrives
Lucid Diagnostics sells EsoGuard, a DNA test that screens chronic heartburn patients for esophageal precancer without an invasive camera procedure. For over a year, the diagnostics maker has waited for a formal Medicare coverage rule to unlock payment for older Americans, who make up roughly half of its target market. "Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test," chief executive Lishan Aklog said.
Instead of waiting for the national rule, the laboratory operator submitted clinical evidence directly to Novitas, the regional contractor that oversees its Texas facility. It began filing claims in late September and received consistent payments in October at the federal fee schedule rate of $1,938.01 per test. The medical technology group immediately shifted its sales reps to target older patients, and monthly test volume jumped past 1,800 in October — a pace that by our math equals more than 5,400 tests a quarter, almost double the 2,871 tests processed in the third quarter.
What to watch: fourth-quarter recognized revenue and the share of October tests billed to Medicare. Consistent cash collection on those 1,800 monthly tests would lift quarterly sales well above the $1.2 million to $1.5 million range where revenue has been stuck for two years.
Medical Guidelines and Private Insurers Add Backing
Private insurers and government hospitals rarely pay for a new diagnostic test until medical societies endorse it and large studies prove it works in practice. During the quarter, the cancer-screening specialist added clinical proof and expanded its early commercial contracts alongside its push into Medicare.
- Medical guidelines: the American Gastroenterological Association released draft guidelines naming EsoGuard and EsoCheck — its cell-collection swab device — as an alternative to endoscopy with "high certainty of evidence".
- Real-world study: a peer-reviewed paper covering 11,991 patients showed a 95% collection success rate in under two minutes with zero device-related adverse events.
- Commercial insurance: five health plans using the Concert laboratory benefit network will adopt coverage by year-end, up from three last quarter.
- Veterans Affairs: the first two VA medical centers launched testing programs, which Lucid expects to be a "meaningful long-term contributor to its commercial activity and revenue".
These endorsements matter because private insurers cover the half of the heartburn population that Medicare does not. Being the only commercial test cited in the draft gastroenterology guidelines gives the sales team stronger leverage to turn coverage policies into paid claims.
What to watch: the final published version of the gastroenterology guidelines and the number of active Veterans Affairs hospitals in the fourth quarter. Steady additions to both will show whether commercial adoption is keeping pace with Medicare.
🐻 Bear Case
Formal Medicare Policy Remains Stuck in a Backlog
"What has been a marathon is now a sprint," chief executive Lishan Aklog said of the October reimbursement breakthrough. Yet the formal Local Coverage Determination (LCD) — the permanent policy from the MolDX Medicare program that would guarantee automatic payment rather than manual review — has still not been published after more than a year of delays.
Lucid noted that its current "claim-by-claim adjudication is independent of the pending MolDX Local Coverage Determination (LCD) reconsideration" and said a meeting with federal officials confirmed "the delay is attributable to an administrative backlog". Meanwhile, third-quarter numbers show how little cash the laboratory collects before broad coverage kicks in: it processed 2,871 tests, up 1.1% from a year ago, but revenue slipped 0.7% to $1.20 million. By our math, recognized revenue per test dropped to $419 from $532 in the second quarter, as the company still books revenue mostly when cash arrives.
Individual claim reviews by a regional contractor can slow down or tighten as claim volume doubles, whereas a published coverage determination locks in rules and lets the laboratory book revenue as soon as it delivers a test report. Until that draft policy appears and finishes its comment period, every batch of Medicare claims still depends on manual review.
What to watch: publication of the draft MolDX coverage policy and the percentage of fourth-quarter Medicare claims paid on the first submission. A drop in payment rates as October's higher volume hits the contractor's desks would show that case-by-case review cannot fully replace a formal rule.
Cash Drop Forces Another Dilutive Financing
Running a national commercial sales team while waiting for insurers to pay requires heavy upfront spending. To pivot its sales reps toward Medicare clinics, Lucid increased GAAP sales and marketing spending by 22.4% from a year ago to $5.25 million. By our math, sales and marketing jumped by 82.2 percentage points of revenue to 436.6%, partially offset by cost of revenues — the laboratory cost of running the tests — falling 23.4 percentage points to 116.7% of revenue.
That commercial push kept the quarterly loss excluding one-offs at $10.6 million, up 2.9% from a year ago. Cash and cash equivalents fell by $15.4 million during the third quarter to $18.0 million, leaving less than two quarters of funding at that pace. To refill its bank account after the quarter closed, the diagnostics group sold $15.0 million of Series C Convertible Preferred Stock to existing investors, lifting cash back to about $33.0 million by our math.
Repeated stock and preferred-share sales keep the business running, but they dilute common shareholders: the weighted average share count rose 76.5% over the past year to 190.9 million. If the October Medicare surge takes months to turn into collected cash, the expanded sales force will keep burning through the new $15.0 million raise.
What to watch: fourth-quarter cash burn against sales and marketing expenses. If Medicare payments arrive promptly at $1,938 per test, quarterly cash consumption should shrink below $10 million for the first time.
Risks this quarter didn't answer
Four standing financial and operational concerns received no update in the third-quarter earnings release, though several may appear in the full quarterly filing or conference call.
- Convertible debt default waiver: noteholders had waived a missed May 2026 Medicare coverage deadline only through August 22, 2026; the release does not state whether the October Novitas payments satisfied the debt terms or required a costly extension.
- Commercial insurance claim approvals: the share of decided claims approved for payment fell from 38% to 28% last quarter; the release gives no third-quarter approval rate.
- Revenue-generating test mix: management previously tracked the share of tests coming from contracted or government payers (just under 40% in the second quarter), which is absent from the release.
- Parent company management fee: Lucid pays its parent, PAVmed, $3.15 million a quarter for shared services — more than double Lucid's quarterly revenue — with no update on whether the fee will come down.
👓 Other Themes
New Billing Codes Prepare Clinics for Easier Claims
Alongside its reimbursement push, the diagnostics maker secured a new Category III Current Procedural Terminology (CPT) billing code for its EsoCheck cell-collection procedure and a proposed International Classification of Diseases (ICD-10) diagnosis code for positive EsoGuard test results. These administrative codes do not guarantee insurance payment on their own, but they make it easier for doctors' offices and hospital electronic health record systems to bill and track the test.
💲 Other KPIs
GAAP net loss attributable to common stockholders narrowed by 35.8% from $10.40 million a year ago, or to $0.03 per share from $0.10. That improvement came from a $5.54 million non-cash accounting gain on the fair value of convertible debt; by our math, excluding that mark, the net loss was $12.22 million.
Weighted average shares outstanding rose 76.5% from 108.2 million a year ago and 4.3% from 183.1 million in the second quarter. The continuous rise reflects spring stock offerings, preferred stock conversions, and dividends paid in shares, before counting any future conversion of the new $15.0 million Series C preferred placement.
Research and development spending fell 7.1% from $1.27 million a year ago as the company shifted budgets toward commercial sales. Excluding stock-based compensation, research and development costs dropped 12.3% to $1.01 million, down for a third consecutive quarter from $1.60 million in the fourth quarter of 2025.
🔮 Guidance
Raised. The company expects five client health plans using the Concert laboratory benefit network to formally adopt coverage for EsoGuard by the end of 2026, up from the three plans reported in the second quarter. Simultaneously, test volume is stepping up after October exceeded 1,800 tests.
❓ Key Questions
How was the expired August 22 debt covenant waiver resolved?
Failure to win a Medicare coverage decision by May 2026 triggered a default clause on $23.5 million of convertible notes, which lenders waived only through August 22, 2026. Investors need to know if October's regional Medicare payments satisfied the lenders or required new concessions.
What conversion price and dividend terms came with Series C?
Lucid raised $15.0 million in Series C Convertible Preferred Stock after quarter-end. Prior preferred shares paid heavy dividends in stock and triggered dilution adjustments near $1.00 per share, so the conversion terms determine how many new common shares this financing creates.
How many October tests went to Medicare patients?
Monthly volume jumped past 1,800 tests in October from a roughly 957-per-month pace in the third quarter. Knowing what fraction of those tests were billed to Novitas at $1,938 apiece tells investors how much cash revenue will actually land in the fourth quarter.
Where is the health-economic cost study promised for this summer?
Last quarter, management said a cost-effectiveness model for EsoGuard would be completed over the summer and submitted for publication to persuade commercial insurers. The third-quarter release highlighted a 11,991-patient clinical study but gave no update on the economic model.